Teal Omics is developing platform technology to accelerate the development of treatments for aging-related diseases. Teal’s technology builds on over 25 years of research conducted in Stanford University's Wyss-Coray lab. Our academic work has focused on developing a deep, molecular understanding of brain aging and neurodegeneration with a specific interest in age-related cognitive decline and Alzheimer’s disease. From this work, we discovered that circulating blood factors can unlock profound insights into brain function, risk of disease, and overall damage accumulated through aging processes.

We started Teal Omics to reshape healthcare with a mission to accelerate the development of disease-modifying drugs for complex aging-related diseases.  We believe that to do this, therapies of the future must target the underlying aging processes that drive early disease progression. Through the novel understanding of aging unlocked by our platform built on advanced proteomics, genomics, and artificial intelligence, we aim to accelerate the development of novel therapeutics that will enable precision medicine aimed at preventing age-related diseases.​​